Active	Status	Sponsor type	Region	Phase	Filter
8 Active 6 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Thomas, Sheeba
NCT00492050: Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia	Active, not recruiting	2	46	US	Bortezomib, Velcade, LDP-341, MLN341, PS-341, Rituximab, Rituxan, Valacyclovir, Valtrex	M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.	Waldenstrom's Macroglobulinemia	02/21	06/26
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia	Completed	1	46	US, RoW	APG2575 400 mg, APG2575 600 mg, APG2575 800 mg	Ascentage Pharma Group Inc.	Waldenstrom Macroglobulinemia	02/24	02/24
Shah, Jatin J
No trials found